The Trans-cutaneous Effects on Physiological Tremor Entertainment During tACS

Sponsor
KU Leuven (Other)
Overall Status
Completed
CT.gov ID
NCT04065022
Collaborator
(none)
22
1
2
6.9
3.2

Study Details

Study Description

Brief Summary

Transcranial alternating current stimulation (tACS) is a noninvasive neuromodulation method that works by passing alternating electric current between electrodes where at least one of them is attached to the head. This has been shown to have effects on the motor system, cognition and behavior. The exact mechanism by which tACS causes such effects is not fully understood. Some studies suggests a contribution from the stimulated peripheral nerves present in the scalp rather than direct brain effects. To test this hypothesis two arms will be done. First, 12 subjects (arm 1) will be stimulated using focused 4x1 montage with gel-filled cup-electrodes over the motor cortex and the effects will be compared between anesthetized and non-anesthetized scalp. The effects of anesthetizing the scalp will be tested on three different stimulation amplitudes off (0 mA), low (0.5 mA) and high (2.5 mA). Then, 10 subjects (arm 2) will be stimulated over the contralateral arm to exclude any direct brain stimulation effects and to test if peripheral nerve stimulation can entrain the tremor. Three outcome measurements will be measured during the experiments which are: tremor entrainment, sensation intensity and sensation threshold.

Condition or Disease Intervention/Treatment Phase
  • Device: tACS at tremor frequency
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
22 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
The Trans-cutaneous Effects on Physiological Tremor Entertainment During tACS
Actual Study Start Date :
Jun 20, 2017
Actual Primary Completion Date :
Jan 16, 2018
Actual Study Completion Date :
Jan 16, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Head stimulation

Each subject will be stimulated at two different days. One day with the presence of topical anesthetic cream on the scalp above the MC and in the other day with absence of the anesthetic cream. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 4*1 gel-filled cup-electrodes is placed over each of motor cortex. Each subject follows three sessions of 12 min length each day. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.

Device: tACS at tremor frequency
tACS applied between the stimulation electrodes at tremor frequency

Experimental: Arm stimulation

Each subject will be stimulated on only one day. Stimulation frequency is set similar to that of the tremor. Three stimulation amplitudes will be tested (0 mA, 0.5 mA and 2.5 mA -reduced if not uncomfortable). A set of 2*1 gel-filled cup-electrodes is placed over the contralateral arm. Each subject follows three sessions of 12 min length. During each session the tremor is measured while interleaving between low amplitude stimulation, high amplitude stimulation and No stimulation. By the end of each session we get 3 min of Low amplitude stimulation, 3 min of high amplitude stimulation and 6 min of No stimulation.

Device: tACS at tremor frequency
tACS applied between the stimulation electrodes at tremor frequency

Outcome Measures

Primary Outcome Measures

  1. Change in tremor-stimulation phase entrainment- Session 1 [During session one of 12 minutes length (6 minutes with stimulation ON and 6 minutes with stimulation OFF)]

    phase locking value was calculated between the tremor signal measured using accelerometer and the stimulation signal

  2. Change in tremor-stimulation phase entrainment- Session 2 [During session two of 12 minutes length (6 minutes with stimulation ON and 6 minutes with stimulation OFF)]

    phase locking value was calculated between the tremor signal measured using accelerometer and the stimulation signal

  3. Change in tremor-stimulation phase entrainment- Session 3 [During session three of 12 minutes length (6 minutes with stimulation ON and 6 minutes with stimulation OFF)]

    phase locking value was calculated between the tremor signal measured using accelerometer and the stimulation signal

Secondary Outcome Measures

  1. Sensation rating [Measured up to 5 minutes before the start of the stimulation sessions and lasts for 10 seconds of stimulation after which the subject gives the rating]

    The subject is asked to rate the sensation intensity during the stimulation at each stimulation amplitude using a visual analog scale from 0 to 10. Zero means the subject doesn't feel the stimulation and the number starts to increase as the sensation perception intensity increases to reach 10 if the subject feels it painful.

  2. Sensation threshold [Measured 3 minutes before the start of the stimulation sessions and lasts up to 2 minutes. Stimulation at each amplitude lasts for 10 seconds]

    Stimulation amplitude at which the subject starts to feel the stimulation. Stimulation starts with 0 mA amplitude and then increased gradually until stimulation is perceived (or reaching maximum amplitude).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Above 18

  • Signed informed consents

Exclusion Criteria:
  • Pregnancy

  • History of Epilepsy

  • Family history of Epilepsy

Contacts and Locations

Locations

Site City State Country Postal Code
1 KU Leuven Leuven Belgium 3000

Sponsors and Collaborators

  • KU Leuven

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Myles Mc Laughlin, Principal Investigator, KU Leuven
ClinicalTrials.gov Identifier:
NCT04065022
Other Study ID Numbers:
  • S57869-1
First Posted:
Aug 22, 2019
Last Update Posted:
Aug 22, 2019
Last Verified:
Aug 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2019